Palivizumab antibody | AbD23967_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with palivizumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using increasing concentrations of HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data for binding to palivizumab is presented as the mean of three measurements
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 0.5 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
A microtiter plate was coated over night with palivizumab at concentrations between 0.5 and 1.5 μg/ml. After washing and blocking with PBST+5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of human anti palivizumab (clone AbD23967_hIgG1). Detection was performed using HRP conjugated palivizumab at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®
Human anti Palivizumab:HRP
Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in fully human IgG1 format for bioanalytical assays to measure palivizumab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
Human anti Palivizumab
Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in fully human IgG1 format for bioanalytical assays to measure palivizumab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD23967_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA262P | E | 0.1 mg | ||||
| HCA262 | E | 0.1 mg |
Human anti Palivizumab, clone AbD23967_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.
Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 (HCA261) in monovalent Fab format.
Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.
View a summary of all anti-palivizumab antibodies
Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 (HCA261) in monovalent Fab format.
Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.
View a summary of all anti-palivizumab antibodies
Product Details
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Palivizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 1.5 nM by real time, label free molecular interaction analysis on immobilized palivizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 12 months from date of despatch.
- Shelf Life
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Synagis® is a registered trademark of the AstraZeneca group of companies.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Palivizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used as a detection reagent in a sandwich ELISA together with HCA261 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a capture or detection antibody together with the same antibody or HCA261 as the paired reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA.
Protocol: PK bridging ELISA to measure free drug
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Palivizumab | HCA261 | 0.1 mg | E | ||
| Human anti Palivizumab | HCA262 | 0.1 mg | E | ||
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Palivizumab | HCA261 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ |
Product Specific References
References for Palivizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent Application US20170315118A1
